<DOC>
	<DOCNO>NCT02343627</DOCNO>
	<brief_summary>This study examine safety , tolerability efficacy NVXT new formulation patient mild-to-moderate fungal infection toe nail .</brief_summary>
	<brief_title>Safety Efficacy NVXT Solution Mild-to-Moderate Fungal Infection Toe Nail</brief_title>
	<detailed_description>This Phase IIa pilot multiple-dose study examine safety , tolerability efficacy NVXT new formulation patient mild-to-moderate fungal infection toe nail .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Clinically diagnose onychomycosis Presence dermatophyte fungal infection current topical systemic antifungal therapy Clinical diagnosis mildtomoderate fungal infection least one toe involve 1050 % nail area , without involvement one lunular proximal region Positive potassium hydroxide mount preparation Positive fungal culture dermatophyte Nail anatomical abnormality toe may interfere evaluation dose compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>